Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma

[1]  L. Qin,et al.  Computational study on novel natural compound inhibitor targeting IDH1_R132H , 2022, Aging.

[2]  Salman Hosawi,et al.  Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells , 2022, International journal of molecular sciences.

[3]  Yang Liu,et al.  IDH mutation and cancer stem cell. , 2022, Essays in biochemistry.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  Marián Hajdúch,et al.  IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis , 2021, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  Yonghua Liu,et al.  Mechanism of IDH1-R132H mutation in T cell acute lymphoblastic leukemia mouse model via the Notch1 pathway. , 2021, Tissue & cell.

[7]  C. Eberhart,et al.  Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1. , 2021, Cancer Letters.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  Mei-lan Liu,et al.  Glycolysis-Related Genes Serve as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma , 2021, Oxidative medicine and cellular longevity.

[10]  C. R. Leemans,et al.  Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.

[11]  A. Wicaksono,et al.  Comparison of Polymerase Chain Reaction–Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas , 2020, Asian Pacific journal of cancer prevention : APJCP.

[12]  T. Owonikoko,et al.  An update on the immune landscape in lung and head and neck cancers , 2020, CA: a cancer journal for clinicians.

[13]  M. Li,et al.  Wild-type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells , 2020, Molecular medicine reports.

[14]  Chawnshang Chang,et al.  Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling. , 2019, Cancer letters.

[15]  F. Sanz,et al.  The DisGeNET knowledge platform for disease genomics: 2019 update , 2019, Nucleic Acids Res..

[16]  Dibson D. Gondim,et al.  Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  A. Lane,et al.  Metabolic reprogramming in tumors: Contributions of the tumor microenvironment , 2019, Genes & diseases.

[18]  S. Pollard,et al.  Experimental models and tools to tackle glioblastoma , 2019, Disease Models & Mechanisms.

[19]  A. Stegh,et al.  Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease , 2019, Science Advances.

[20]  S. Aubert,et al.  IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract. , 2019, Human pathology.

[21]  Jan Gorodkin,et al.  Cytoscape stringApp: Network analysis and visualization of proteomics data , 2018, bioRxiv.

[22]  Yanjun Wang,et al.  IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5 , 2018, Royal Society Open Biology.

[23]  Jin Zhang,et al.  Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma , 2018, BMC Cancer.

[24]  Mary Goldman,et al.  The UCSC Xena platform for public and private cancer genomics data visualization and interpretation , 2018, bioRxiv.

[25]  Qinxi Li,et al.  IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53 , 2018, The Journal of Biological Chemistry.

[26]  T. Fu,et al.  Isocitrate dehydrogenase 1–snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability , 2018, Breast Cancer Research.

[27]  G. Weinstein,et al.  Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Hamoud H. Al-Khallaf.  Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight , 2017, Cell & Bioscience.

[29]  M. Esteller,et al.  Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas , 2017, Clinical Cancer Research.

[30]  Q. Song,et al.  Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma , 2016, Oncotarget.

[31]  Xudong Wang,et al.  Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer , 2016, Oncotarget.

[32]  K. Yen,et al.  IDH mutations in cancer and progress toward development of targeted therapeutics. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  C. James,et al.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. , 2015, Cell reports.

[34]  Tomas Radivoyevitch,et al.  The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. , 2014, Biochimica et biophysica acta.

[35]  A. Sikora,et al.  Survival outcomes in advanced laryngeal cancer. , 2014, JAMA otolaryngology-- head & neck surgery.

[36]  J. Stebbing,et al.  IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. , 2013, Future oncology.

[37]  Ping Zhang,et al.  Plasma Membrane Proteomics of Tumor Spheres Identify CD166 as a Novel Marker for Cancer Stem-like Cells in Head and Neck Squamous Cell Carcinoma* , 2013, Molecular & Cellular Proteomics.

[38]  T. Mak,et al.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. , 2013, Cancer discovery.

[39]  D. Margolis,et al.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.

[40]  Hui Yang,et al.  IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives , 2012, Clinical Cancer Research.

[41]  S. Inoue,et al.  D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. , 2012, Genes & development.

[42]  R. Bristow,et al.  IDH mutation status in prostate cancer , 2012, Oncogene.

[43]  K. Aldape,et al.  Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. , 2012, Annals of diagnostic pathology.

[44]  K. Smolková,et al.  The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells , 2012, International journal of cell biology.

[45]  K. Sharp,et al.  Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production , 2012, Oncogene.

[46]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[47]  C. Auewarakul,et al.  Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients , 2012, Journal of Hematology & Oncology.

[48]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[49]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[50]  G. Ming,et al.  Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond , 2011, Cell cycle.

[51]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[52]  O. Chinot,et al.  IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients , 2011, Journal of Neuro-Oncology.

[53]  Joseph G Boyer,et al.  A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. , 2011, Biochemistry.

[54]  T. Shibata,et al.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. , 2011, The American journal of pathology.

[55]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[56]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[57]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Hai Yan,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.

[59]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[61]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[62]  N. Yoo,et al.  Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers , 2009, International journal of cancer.

[63]  M. Koch,et al.  Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse , 2009, British Journal of Cancer.

[64]  D. Louis,et al.  Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. , 2009 .

[65]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[66]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[67]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[68]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[69]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[70]  M. Jensen,et al.  A Pyruvate Cycling Pathway Involving Cytosolic NADP-dependent Isocitrate Dehydrogenase Regulates Glucose-stimulated Insulin Secretion* , 2006, Journal of Biological Chemistry.

[71]  D. Grignon,et al.  Clear cell renal cell carcinoma. , 2005, Clinics in laboratory medicine.

[72]  Jianping Ding,et al.  Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity* , 2004, Journal of Biological Chemistry.

[73]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[74]  P. Shannon,et al.  Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks , 2003 .

[75]  T. Huh,et al.  Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. , 2002, Free radical biology & medicine.

[76]  D. Koshland,et al.  Structure of isocitrate dehydrogenase with isocitrate, nicotinamide adenine dinucleotide phosphate, and calcium at 2.5-A resolution: a pseudo-Michaelis ternary complex. , 1993, Biochemistry.

[77]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[78]  V. ´. õdeÿ.  The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells , 2012 .

[79]  M. J. van den Bent,et al.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.

[80]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.